Take a deeper dive

News & Events

Nuventra Named One of America’s Fastest Growing Private Companies Two Years in a Row

Inc. Magazine announced on Wednesday that Nuventra Pharma Sciences — the pharmaceutical industry’s go-to resource for clinical pharmacology, pharmacokinetic and pharmacometric consulting services — has made the 2015 Inc. 5000 list. This marks the second year in a row that Nuventra has been recognized as one of America’s fastest growing private companies.  This year, Nuventra is the sixth fastest growing company in North Carolina’s health sector.

“It’s an honor to make the Inc. 5000 list again this year”, stated Geoffrey Banks, Ph.D., Nuventra’s President and CEO. “It is exciting to see the company continue to grow and serve an unmet need in the drug development industry around clinical pharmacology, PK/PD and pharmacometrics.”

Nuventra’s growth continues as a new office opens this month in Colorado.  Along with offices in Durham, NC; Philadelphia, PA; and Wilmington, NC, the Nuventra team is extending its reach as well as its ability to provide expert PK/PD services to the pharmaceutical industry. This accomplishment reflects tremendous hard work and dedication to meeting our client’s needs.

Click here for the complete list and for more information about what being an Inc. 5000 Company means.

More About Nuventra Pharma Sciences

Founded in 2008, Nuventra is the pharmaceutical industry’s go-to resource for clinical pharmacology, pharmacokinetic, and pharmacometric consulting services. Nuventra gives pharmaceutical companies and CROs rare access to a hands-on team of industry-leading consultants experienced in complex studies and analyses. We embrace the notion that simplicity and clarity lead to good decisions by taking complex pharmacokinetic and pharmacometric principals and making them understandable and usable for common sense drug development. Nuventra’s flexible business structure enables us to integrate with our clients and help them maximize the potential of clinical pharmacology studies and pharmacokinetic analyses to pave the way toward marketing approval.

Back